EE-Tartu-TARTU
Tartu, Estonia
1 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Acute Myeloid Leukemia, Adult
Stichting Hemato-Oncologie voor Volwassenen Nederland448 enrolled201 locationsNCT06652438
Recruiting
Phase 3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland227 enrolled119 locationsNCT07075016